nifedipine has been researched along with Coronary Artery Disease in 54 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the impact of short-acting and extended release nifedipine on sympathetic activity using radiotracer methodology in patients with stable coronary artery disease in order to more accurately document the response of the sympathetic nervous system to different formulations of this dihydropyridine calcium channel antagonist." | 9.34 | Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease. ( D' Iorio, M; Floras, JS; Parker, JD; Toal, CB, 2020) |
| "The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects." | 9.12 | Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Vokó, Z, 2007) |
| "These results indicate that nifedipine more effectively prevented admission for angina pectoris by inhibiting the progression of coronary artery disease in patients with a history of MI." | 9.12 | Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). ( Haze, K; Hirayama, A; Hosoda, S; Kawai, C; Kodama, K; Nonogi, H; Shinoda, E; Sumiyoshi, T; Yui, Y, 2007) |
| "The Japan Multicenter Investigation for Cardiovascular Diseases-B was performed to investigate whether nifedipine retard treatment was associated with a significantly higher incidence of cardiac events than angiotensin converting enzyme inhibitor treatment in Japanese patients." | 9.11 | Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. ( Arakawa, K; Hirayama, A; Hosoda, S; Iimura, O; Ishii, M; Kanmatsuse, K; Kawai, C; Kodama, K; Nonogi, H; Origasa, H; Saruta, T; Sumiyoshi, T; Yui, Y, 2004) |
| "The salutary effects of the addition of nifedipine GITS to the basic regimen of patients with concurrent stable symptomatic coronary artery disease and hypertension emphasize the need for blood pressure control." | 9.11 | Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Wagener, G, 2005) |
| "The effects of nifedipine on inflammation and endothelial function in the coronary circulation were studied in patients who had angina pectoris (n = 17)." | 9.11 | Effect of nifedipine on C-reactive protein levels in the coronary sinus and on coronary blood flow in response to acetylcholine in patients with stable angina pectoris having percutaneous coronary intervention. ( Dohi, Y; Goto, T; Hayashi, K; Ikeda, K; Nakazawa, A; Sato, K; Sugiura, T; Sugiyama, M; Takase, H; Toriyama, T; Ueda, R, 2005) |
| " Fifteen male patients with stable angina pectoris treated with atenolol were studied after undergoing routine cardiac catheterisation." | 9.07 | A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "425 patients showing mild coronary artery disease (CAD) on arteriography were enrolled in a multicentre trial and randomised to treatment with nifedipine (80 mg/day) or placebo." | 9.06 | Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. ( Deckers, JW; Hecker, H; Hugenholtz, PG; Jost, S; Lichtlen, PR; Rafflenbeul, W, 1990) |
| "Addition of nifedipine GITS to the treatment regimen of selected patient groups with symptomatic coronary artery disease results in a significant reduction of cardiovascular morbidity." | 7.76 | Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the "ACTION" database. ( Elliott, HL; Meredith, PA, 2010) |
| "To investigate the effects of nifedipine on endothelial function in coronary artery (CA) and brachial artery (BA) in coronary artery disease (CAD), we measured vasodilator responses of CA and BA to acetylcholine (ACh, endothelium-dependent dilation) in 13 patients (63+/-10 years old) with CAD before and after sublingual administration of nifedipine 10 mg." | 7.73 | Beneficial effects of nifedipine on vasodilator response to acetylcholine in coronary and brachial arteries in the patients with coronary artery disease. ( Akima, T; Hamabe, A; Ishihara, M; Kurita, A; Ohsuzu, F; Satomura, K; Takase, B; Uehata, A, 2006) |
| " In selected population of 113 patients with effort angina and proven coronary artery disease, the coronary cineangiographic pattern after 2 year therapy with nifedipine (Group 1, 39 patients), propranolol (Group 2, 36 patients), or isosorbide dinitrate (control group, 38 patients) was compared to the pre-treatment pattern." | 7.67 | [Angiographic course of coronary atherosclerosis in angina pectoris. Its relation to 2 years' treatment with propranolol, nifedipine and nitrates]. ( De Cesare, N; Fabbiocchi, F; Guazzi, M; Guazzi, MD; Loaldi, A; Montorsi, P; Polese, A; Ravagnani, P, 1989) |
| "Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent." | 6.45 | Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. ( Beckey, C; Lundy, A; Lutfi, N, 2009) |
| "We investigated the impact of short-acting and extended release nifedipine on sympathetic activity using radiotracer methodology in patients with stable coronary artery disease in order to more accurately document the response of the sympathetic nervous system to different formulations of this dihydropyridine calcium channel antagonist." | 5.34 | Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease. ( D' Iorio, M; Floras, JS; Parker, JD; Toal, CB, 2020) |
| "Hypertensive patients with coronary artery disease were randomly assigned to the nifedipine retard (n = 108) or ACE inhibitors groups (n = 102) and treated for 3 years." | 5.14 | Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease. ( Haze, K; Hirayama, A; Hosoda, S; Iwanaga, Y; Kawai, C; Kodama, K; Nishio, R; Nonogi, H; Sumiyoshi, T; Yui, N; Yui, Y, 2010) |
| "The stroke and heart failure risk reduction by nifedipine GITS in patients with stable angina can be attributed partly to its BP lowering effect, whereas effects on coronary procedures are likely to be related almost entirely to its antianginal effects." | 5.12 | Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Vokó, Z, 2007) |
| "These results indicate that nifedipine more effectively prevented admission for angina pectoris by inhibiting the progression of coronary artery disease in patients with a history of MI." | 5.12 | Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). ( Haze, K; Hirayama, A; Hosoda, S; Kawai, C; Kodama, K; Nonogi, H; Shinoda, E; Sumiyoshi, T; Yui, Y, 2007) |
| "The Japan Multicenter Investigation for Cardiovascular Diseases-B was performed to investigate whether nifedipine retard treatment was associated with a significantly higher incidence of cardiac events than angiotensin converting enzyme inhibitor treatment in Japanese patients." | 5.11 | Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. ( Arakawa, K; Hirayama, A; Hosoda, S; Iimura, O; Ishii, M; Kanmatsuse, K; Kawai, C; Kodama, K; Nonogi, H; Origasa, H; Saruta, T; Sumiyoshi, T; Yui, Y, 2004) |
| "The salutary effects of the addition of nifedipine GITS to the basic regimen of patients with concurrent stable symptomatic coronary artery disease and hypertension emphasize the need for blood pressure control." | 5.11 | Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. ( de Brouwer, S; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Wagener, G, 2005) |
| "The effects of nifedipine on inflammation and endothelial function in the coronary circulation were studied in patients who had angina pectoris (n = 17)." | 5.11 | Effect of nifedipine on C-reactive protein levels in the coronary sinus and on coronary blood flow in response to acetylcholine in patients with stable angina pectoris having percutaneous coronary intervention. ( Dohi, Y; Goto, T; Hayashi, K; Ikeda, K; Nakazawa, A; Sato, K; Sugiura, T; Sugiyama, M; Takase, H; Toriyama, T; Ueda, R, 2005) |
| " The study was designed as a side arm of INSIGHT (International Nifedipine Study: Intervention as Goal for Hypertension Therapy), aimed to show the efficacy of nifedipine once daily versus co-amilozide (hydrochlorothiazide 25 mg, amiloride 2." | 5.09 | Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. ( Motro, M; Shemesh, J, 2001) |
| " Fifteen male patients with stable angina pectoris treated with atenolol were studied after undergoing routine cardiac catheterisation." | 5.07 | A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "425 patients showing mild coronary artery disease (CAD) on arteriography were enrolled in a multicentre trial and randomised to treatment with nifedipine (80 mg/day) or placebo." | 5.06 | Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. ( Deckers, JW; Hecker, H; Hugenholtz, PG; Jost, S; Lichtlen, PR; Rafflenbeul, W, 1990) |
| "It is the objective of the INTACT-study to test in man, whether a significant retardation of the progression of coronary artery disease is attainable with the Ca-antagonist nifedipine; this may be possible on the basis of numerous animal experiments." | 5.06 | Clinical application of quantitative coronary angiography using the CAAS system: preliminary results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy). ( Deckers, JW; Hecker, H; Hugenholtz, PG; Jost, S; Lichtlen, PR; Nellessen, U; Rafflenbeul, W; Reiber, JH, 1988) |
| "6 years, 54% men), a subgroup of 544 participants in the calcification side arm of the INSIGHT (International Nifedipine Study Intervention as Goal for Hypertension Therapy)." | 3.79 | Progression of coronary artery calcification is associated with long-term cardiovascular events in hypertensive adults. ( Apter, S; Grossman, C; Grossman, E; Morag-Koren, N; Motro, M; Shemesh, J, 2013) |
| "Addition of nifedipine GITS to the treatment regimen of selected patient groups with symptomatic coronary artery disease results in a significant reduction of cardiovascular morbidity." | 3.76 | Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the "ACTION" database. ( Elliott, HL; Meredith, PA, 2010) |
| "To investigate the effects of nifedipine on endothelial function in coronary artery (CA) and brachial artery (BA) in coronary artery disease (CAD), we measured vasodilator responses of CA and BA to acetylcholine (ACh, endothelium-dependent dilation) in 13 patients (63+/-10 years old) with CAD before and after sublingual administration of nifedipine 10 mg." | 3.73 | Beneficial effects of nifedipine on vasodilator response to acetylcholine in coronary and brachial arteries in the patients with coronary artery disease. ( Akima, T; Hamabe, A; Ishihara, M; Kurita, A; Ohsuzu, F; Satomura, K; Takase, B; Uehata, A, 2006) |
| " In selected population of 113 patients with effort angina and proven coronary artery disease, the coronary cineangiographic pattern after 2 year therapy with nifedipine (Group 1, 39 patients), propranolol (Group 2, 36 patients), or isosorbide dinitrate (control group, 38 patients) was compared to the pre-treatment pattern." | 3.67 | [Angiographic course of coronary atherosclerosis in angina pectoris. Its relation to 2 years' treatment with propranolol, nifedipine and nitrates]. ( De Cesare, N; Fabbiocchi, F; Guazzi, M; Guazzi, MD; Loaldi, A; Montorsi, P; Polese, A; Ravagnani, P, 1989) |
| "We examined the progression of coronary atherosclerosis, as measured by dual-section spiral computed tomography, using the total coronary artery calcium score as a quantitative measure of the burden of atherosclerosis." | 2.71 | Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. ( Bursztyn, M; Grossman, E; Motro, M; Shemesh, J, 2003) |
| "The changes were not correlated with stenosis length and plaque area." | 2.67 | Evolution of coronary stenoses is related to baseline severity--a prospective quantitative angiographic analysis in patients with moderate coronary disease. INTACT Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy. ( Deckers, JW; Hecker, H; Jost, S; Lichtlen, PR; Lippolt, P; Nikutta, P; Rafflenbeul, W; Wiese, B, 1994) |
| "Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent." | 2.45 | Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. ( Beckey, C; Lundy, A; Lutfi, N, 2009) |
| "This study was conducted retrospectively to elucidate whether the long-term use of nifedipine is effective against the progression of coronary atherosclerosis in humans." | 1.28 | Effect of nifedipine on the progression of coronary atherosclerosis in humans. Analysis of coronary angiogram by videodensitometry. ( Akishita, M; Orimo, H; Ouchi, Y; Yabe, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (16.67) | 18.7374 |
| 1990's | 20 (37.04) | 18.2507 |
| 2000's | 19 (35.19) | 29.6817 |
| 2010's | 5 (9.26) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Parker, JD | 2 |
| D' Iorio, M | 1 |
| Floras, JS | 1 |
| Toal, CB | 1 |
| Shemesh, J | 3 |
| Motro, M | 3 |
| Grossman, C | 1 |
| Morag-Koren, N | 1 |
| Apter, S | 1 |
| Grossman, E | 2 |
| Meredith, PA | 3 |
| Lloyd, SM | 2 |
| Ford, I | 2 |
| Elliott, HL | 3 |
| Lüscher, TF | 1 |
| Pieper, M | 1 |
| Tendera, M | 1 |
| Vrolix, M | 1 |
| Rutsch, W | 1 |
| van den Branden, F | 1 |
| Gil, R | 1 |
| Bischoff, KO | 1 |
| Haude, M | 1 |
| Fischer, D | 1 |
| Meinertz, T | 1 |
| Münzel, T | 1 |
| Lundy, A | 1 |
| Lutfi, N | 1 |
| Beckey, C | 1 |
| Ganz, P | 2 |
| Ho, JE | 1 |
| Hsue, PY | 1 |
| Yui, Y | 4 |
| Kodama, K | 4 |
| Hirayama, A | 4 |
| Nishio, R | 1 |
| Iwanaga, Y | 1 |
| Nonogi, H | 4 |
| Haze, K | 3 |
| Sumiyoshi, T | 4 |
| Yui, N | 1 |
| Hosoda, S | 4 |
| Kawai, C | 4 |
| Donaldson, KM | 1 |
| Dawkins, KD | 1 |
| Waller, DG | 1 |
| Bursztyn, M | 1 |
| Kanmatsuse, K | 1 |
| Origasa, H | 1 |
| Iimura, O | 1 |
| Ishii, M | 1 |
| Saruta, T | 1 |
| Arakawa, K | 1 |
| Fagard, RH | 1 |
| Lubsen, J | 6 |
| Wagener, G | 1 |
| Kirwan, BA | 5 |
| de Brouwer, S | 5 |
| Poole-Wilson, PA | 5 |
| Shinoda, E | 2 |
| Takase, H | 1 |
| Toriyama, T | 1 |
| Sugiyama, M | 1 |
| Nakazawa, A | 1 |
| Hayashi, K | 1 |
| Goto, T | 1 |
| Sugiura, T | 1 |
| Ikeda, K | 1 |
| Sato, K | 1 |
| Ueda, R | 1 |
| Dohi, Y | 1 |
| Takase, B | 1 |
| Hamabe, A | 1 |
| Satomura, K | 1 |
| Akima, T | 1 |
| Uehata, A | 1 |
| Ohsuzu, F | 1 |
| Ishihara, M | 1 |
| Kurita, A | 1 |
| Otterstad, JE | 2 |
| Fox, KA | 1 |
| Corell, P | 1 |
| Celik, T | 1 |
| Kursaklioglu, H | 1 |
| Iyisoy, A | 1 |
| Yuksel, C | 1 |
| Isik, E | 1 |
| Dart, AM | 1 |
| Danchin, N | 1 |
| Battler, A | 1 |
| Bayes de Luna, A | 1 |
| Dunselman, PH | 1 |
| Glasser, S | 1 |
| Koudstaal, PJ | 1 |
| Sutton, G | 1 |
| van Dalen, FJ | 1 |
| Vokó, Z | 1 |
| Takatsu, F | 1 |
| Nishiyama, A | 1 |
| Shiga, Y | 1 |
| Watarai, M | 1 |
| Shimizu, S | 1 |
| Nayler, WG | 1 |
| Just, H | 1 |
| Frey, M | 1 |
| Jost, S | 6 |
| Deckers, JW | 3 |
| Nikutta, P | 2 |
| Wiese, B | 3 |
| Rafflenbeul, W | 6 |
| Hecker, H | 6 |
| Lippolt, P | 3 |
| Lichtlen, PR | 6 |
| Raby, KE | 1 |
| Vita, JA | 1 |
| Rocco, MB | 1 |
| Yeung, AC | 1 |
| Fantasia, G | 1 |
| Barry, J | 1 |
| Selwyn, AP | 1 |
| Deckers, J | 3 |
| Reiber, JH | 3 |
| Riedel, M | 1 |
| Nolte, CW | 1 |
| Kato, H | 1 |
| Okada, R | 1 |
| Enoki, M | 1 |
| Oogushi, K | 1 |
| Emura, S | 1 |
| Takashima, T | 1 |
| Ohmori, K | 1 |
| Garganeeva, AA | 1 |
| Tepliakov, AT | 1 |
| Chernov, VI | 1 |
| Braslavskaia, TG | 1 |
| Boev, SS | 1 |
| Vaidya, S | 1 |
| Walwaikar, P | 1 |
| Kadhe, G | 1 |
| Arakawa, H | 1 |
| Mutoh, S | 1 |
| Hirosumi, J | 1 |
| Yamaguchi, I | 1 |
| Waters, D | 1 |
| Lespérance, J | 1 |
| Ouchi, Y | 1 |
| Akishita, M | 1 |
| Yabe, Y | 1 |
| Orimo, H | 1 |
| Hugenholtz, PG | 5 |
| Brophy, JM | 1 |
| Burton, JR | 1 |
| Haraphongse, M | 1 |
| Hsu, L | 1 |
| Kappagoda, CT | 1 |
| Rossall, RE | 1 |
| Schlaut, B | 1 |
| Senaratne, MP | 1 |
| Nellessen, U | 3 |
| Henry, PD | 1 |
| Neumann, E | 1 |
| Günther, KH | 1 |
| Romaniuk, P | 1 |
| Strangfeld, D | 1 |
| Loaldi, A | 1 |
| Fabbiocchi, F | 1 |
| Montorsi, P | 1 |
| Guazzi, M | 1 |
| Polese, A | 1 |
| De Cesare, N | 1 |
| Ravagnani, P | 1 |
| Guazzi, MD | 1 |
| Lundholm, CE | 1 |
| Sundbom, L | 1 |
| Lundholm, L | 1 |
| Núñez Jáuregui, P | 1 |
| Tijssen, JG | 1 |
| Simoons, ML | 1 |
| de Feijter, PJ | 1 |
| Bertrand, ME | 1 |
| Lablanche, JM | 1 |
| Fourrier, JL | 1 |
| Traisnel, G | 1 |
| Winniford, MD | 1 |
| Jansen, DE | 1 |
| Reynolds, GA | 1 |
| Apprill, P | 1 |
| Black, WH | 1 |
| Hillis, LD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GLOBAL LEADERS Adjudication Sub-Study[NCT03231059] | 7,365 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Evaluation of the Efficacy of Natural Senolytic Agents and NLRP3 Inhibitors in Treatment of Osteoarthritis: Randomized, Double Blinded ,Placebo Controlled Trial[NCT05276895] | 60 participants (Anticipated) | Interventional | 2022-07-01 | Suspended (stopped due to unavailability of drugs) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for nifedipine and Coronary Artery Disease
| Article | Year |
|---|---|
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Coronary | 2009 |
Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Coronary Artery Disease; Diltiazem; Humans; Nife | 1994 |
Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers.
Topics: Animals; Calcium Channel Blockers; Coronary Artery Disease; Disease Models, Animal; Heart Transplant | 1992 |
Nifedipine and metoprolol in suspected unstable angina. Unstable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Clinical T | 1987 |
24 trials available for nifedipine and Coronary Artery Disease
| Article | Year |
|---|---|
Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease.
Topics: Blood Pressure; Calcium Channel Blockers; Cardiac Output; Coronary Artery Disease; Delayed-Action Pr | 2020 |
Importance of sustained and "tight" blood pressure control in patients with high cardiovascular risk.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardio | 2016 |
Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardio | 2016 |
A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study.
Topics: Acetylcholine; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Pressure; Calcium Channel Blockers | 2009 |
Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Coronary Ar | 2010 |
Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).
Topics: Acetylcholine; Adult; Calcium Channel Blockers; Cholesterol; Coronary Artery Disease; Double-Blind M | 2003 |
A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Calcium Channel | 1993 |
Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation.
Topics: Aged; Benzothiadiazines; Calcinosis; Calcium Channel Blockers; Coronary Artery Disease; Diuretics; F | 2003 |
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Asian People; Blood Pressure; Calcium Channel Blocke | 2004 |
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Corona | 2005 |
Effect of nifedipine on C-reactive protein levels in the coronary sinus and on coronary blood flow in response to acetylcholine in patients with stable angina pectoris having percutaneous coronary intervention.
Topics: Acetylcholine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Flow Velocity; C-Reactiv | 2005 |
Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study.
Topics: Angina Pectoris; Biomarkers; Calcium Channel Blockers; Chronic Disease; Coronary Artery Disease; Cor | 2007 |
Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience.
Topics: Adult; Coronary Artery Disease; Humans; Nifedipine; Placebos; Sentinel Surveillance; Treatment Outco | 2007 |
Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output, Low; Clinical Trials as T | 2007 |
Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
Topics: Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Coronary Angiograph | 2007 |
Evolution of coronary stenoses is related to baseline severity--a prospective quantitative angiographic analysis in patients with moderate coronary disease. INTACT Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy.
Topics: Constriction, Pathologic; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Double-Bl | 1994 |
Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Follow | 1993 |
Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics.
Topics: Aged; Amiloride; Calcinosis; Calcium Channel Blockers; Cardiomyopathies; Coronary Artery Disease; Di | 2001 |
Evaluation of anti-atherosclerotic and vasculoprotective effect of long acting nifedipine in patients after PTCA.
Topics: Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Artery Disease; Delayed-Action Pr | 2001 |
Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.
Topics: Administration, Oral; Aged; Coronary Artery Disease; Drug Administration Schedule; Drug Evaluation; | 1990 |
Features of the angiographic evaluation of the INTACT study. International Nifedipine Trial on Antiatherosclerotic Therapy.
Topics: Angiography; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Evaluation Studies as | 1990 |
[Computer-assisted geometric measuring technic in coronary angiography interval studies: results of initial angiograms of the International Nifedipine Trial of Anti-atherosclerotic Therapy (INTACT) study].
Topics: Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Doubl | 1989 |
Nifedipine and metoprolol in suspected unstable angina. Unstable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Clinical T | 1987 |
Clinical application of quantitative coronary angiography using the CAAS system: preliminary results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).
Topics: Angiography; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Germany, West; Huma | 1988 |
27 other studies available for nifedipine and Coronary Artery Disease
| Article | Year |
|---|---|
Progression of coronary artery calcification is associated with long-term cardiovascular events in hypertensive adults.
Topics: Adult; Aged; Calcinosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Vessels; Disease | 2013 |
Structural and functional manifestations of human atherosclerosis: do they run in parallel?
Topics: Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Human | 2009 |
Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the "ACTION" database.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Coronary Artery Disease; Databases, Factua | 2010 |
Benefits and safety of long-acting calcium antagonists in coronary artery disease: the Action Trial.
Topics: Calcium Channel Blockers; Coronary Artery Disease; Humans; Hypertension; Nifedipine; Randomized Cont | 2005 |
Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Angiography; Coronary Artery Disease; Disea | 2005 |
Beneficial effects of nifedipine on vasodilator response to acetylcholine in coronary and brachial arteries in the patients with coronary artery disease.
Topics: Acetylcholine; Brachial Artery; Calcium Channel Blockers; Coronary Artery Disease; Coronary Vessels; | 2006 |
Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease.
Topics: Aged; Atrial Fibrillation; Calcium Channel Blockers; Coronary Artery Disease; Female; Humans; Incide | 2006 |
Nifedipine improves coronary and peripheral endothelial function in patients with coronary artery disease: are calcium channel blockers acquitted on the charges?
Topics: Calcium Channel Blockers; Coronary Artery Disease; Endothelium, Vascular; Humans; Nifedipine | 2007 |
Long-term follow-up of coronary narrowing with spasm.
Topics: Angina Pectoris, Variant; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Vasospasm | 1994 |
Therapeutic approaches to the control of coronary atherosclerosis.
Topics: Animals; Aorta; Calcium; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Diet, Atherogen | 1994 |
Changing vasomotor responses of coronary arteries to nifedipine.
Topics: Cardiac Catheterization; Circadian Rhythm; Coronary Angiography; Coronary Artery Disease; Coronary C | 1993 |
The antiatherogenic effect of nifedipine on intramural small coronary arterial lesions in cholesterol-fed rabbits.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Cholesterol; Cholesterol, Dietary; Coronary | 1998 |
[Adalat effects on clinical course of coronary heart disease, peripheral circulation and myocardial perfusion in patients with stenosing coronary atherosclerosis].
Topics: Adult; Blood Flow Velocity; Calcium Channel Blockers; Coronary Artery Disease; Coronary Circulation; | 1998 |
[Effects of fenigidin treatment regimen on the state of peripheral hemodynamics of patients with stable effort angina pectoris and postinfarction cardiosclerosis].
Topics: Angina Pectoris; Arm; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Female; Hem | 1998 |
Effect of nilvadipine on balloon catheterization-induced intimal thickening of the coronary artery in miniature pigs.
Topics: Angioplasty, Balloon, Coronary; Animals; Calcium Channel Blockers; Catheterization; Coronary Artery | 1992 |
Effect of nifedipine on the progression of coronary atherosclerosis in humans. Analysis of coronary angiogram by videodensitometry.
Topics: Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Nifedipine; Retros | 1991 |
Finding the magic pill: INTACT revisited.
Topics: Coronary Artery Disease; Humans; Nifedipine | 1991 |
Finding the magic pill: INTACT revisited.
Topics: Coronary Artery Disease; Humans; Nifedipine | 1991 |
Risk stratification after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Discriminant Analysi | 1990 |
Calcium channel blockers and progression of coronary artery disease.
Topics: Angiography; Animals; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Angiography; Coro | 1990 |
[German INTACT Symposium. Results of the INTACT Study: inhibition of the progression of coronary sclerosis using nifedipine. 20-21 January 1990, Hannover].
Topics: Coronary Artery Disease; Humans; Nifedipine | 1990 |
[Differential therapy of myocardial ischemia in females].
Topics: Administration, Sublingual; Adult; Coronary Artery Disease; Coronary Circulation; Coronary Disease; | 1989 |
[Angiographic course of coronary atherosclerosis in angina pectoris. Its relation to 2 years' treatment with propranolol, nifedipine and nitrates].
Topics: Adult; Angina Pectoris; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Isosorbide Dinit | 1989 |
Relationship between coronary atherosclerosis and "sudden cardiac death". Effects of age and calcium blockers in hypercholesterolemic mini-pigs.
Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Vessels; Death, Sudden; Female; Hypercholest | 1989 |
[Use of nifedipine in patients with advanced arteriosclerotic cardiopathy].
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Cardiac Output, Low; Coronary Artery Diseas | 1986 |
Percutaneous transluminal coronary angioplasty in patients with spasm superimposed on atherosclerotic narrowing.
Topics: Angioplasty, Balloon; Combined Modality Therapy; Coronary Artery Disease; Coronary Vasospasm; Dipyri | 1987 |
Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cardiac Pacing, Artificial; Coronary Artery D | 1987 |